ALDH1A1 and metabolic dysfunction-associated steatotic liver disease: Discoveries regarding the mechanisms of ALDH1 in nonneoplastic diseases have established this family of enzymes as a highly promising therapeutic target for conditions such as NAFLD, PD, OA, and CVDs, where its expression downregulation primarily leads to the loss of protective functions.